辉瑞溢价收购Array BioPharma，旨在通过后者的Braftovi、Mektovi完善产品线，但是Array对这两款产品的商业化权利只剩下北美了。 6月 ...

2019年07月08日/生物谷BIOON/--Array BioPharma是一家专注于发现、开发和商业化小分子药物治疗癌症的美国生物制药公司。今年6月 ...

BOULDER, Colo., May 9, 2017 /PRNewswire/ -- Array BioPharma (Nasdaq: ARRY) today announced top-line results from Part 2 of the Phase 3 COLUMBUS study evaluating binimetinib, a MEK inhibitor, and ...

Array BioPharma And Pierre Fabre Announce Development And Commercialization Collaboration For Two Novel Oncology Products, Binimetinib And Encorafenib - Array to receive a $30 million up-front payment ...

After years of disappointments from its MEK inhibitor selumetinib, AstraZeneca got a welcome reprieve from the FDA. (FDA) Ever since AstraZeneca licensed the experimental MEK 1/2 inhibitor selumetinib ...